Cancer cell selective infection and lysis via retroviral replication

The entry "Cancer cell selective infection/lysis via retroviral replication" does not refer to a single molecular target, receptor, or protein. Instead, it describes a therapeutic strategy that uses engineered retroviruses—often as vectors—to selectively infect and lyse cancer cells through their natural life cycle. Retroviruses are enveloped RNA viruses that replicate by integrating their DNA into the host genome using viral enzymes like reverse transcriptase and integrase. This property is exploited both for gene therapy applications and for oncolytic virotherapy strategies aimed at targeting cancer cells. However, this approach is associated with significant safety concerns. Retroviral integration can activate nearby proto-oncogenes through promoter/enhancer insertion or disrupt normal gene function by truncating transcripts—mechanisms collectively known as insertional mutagenesis—which has led to leukemia in some clinical trials involving retroviral vectors for gene therapy[1][5]. While self-inactivating vector designs have improved safety profiles, the risk remains notable. In summary, "Cancer cell selective infection/lysis via retroviral replication" is not itself a canonical molecular target but rather describes an approach leveraging the biology of retroviruses for therapeutic purposes. It should not be listed alongside defined targets such as receptors or enzymes. If you need structured information about specific molecules involved in this process—such as "Retrovirus integrase," "Retrovirus envelope glycoprotein," etc.—please specify which component you wish detailed information about.

For antiretrovirals: Inhibition of reverse transcriptase or integrase enzymes to block viral replication[3].